Company profile
Biomea Fusion, Inc.
NASDAQ:BMEABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Icovamenib | phase2 | — | 4 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05918692 | phase1 | active_not_recruiting | 2023-07-26 | 2026-04-01 | Biomea Fusion Inc. | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia |
| NCT07254286 | phase1 | completed | 2025-09-11 | 2026-01-14 | Biomea Fusion Inc. | Food Effect Study in Healthy Volunteers |
| NCT06152042 | phase2 | completed | 2023-12-28 | 2025-05-20 | Biomea Fusion Inc. | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus |
| NCT07502508 | phase2 | recruiting | 2026-04-30 | 2027-06-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy |
| NCT07502495 | phase2 | active_not_recruiting | 2026-03-27 | 2027-03-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets |
FDA applications (0)
No records yet.